Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(1):27-37
Article Links
Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients
Konstantinos Thomas1, Argiro Lazarini1, Evripidis Kaltsonoudis2, Alexandros Drosos2, Ioannis Papalopoulos3, Prodromos Sidiropoulos3, Pelagia Katsimbri1, Dimitrios Boumpas1, Panagiota Tsatsani4, Sousana Gazi4, Kalliopi Fragkiadaki1, Maria Tektonidou1, Petros P. Sfikakis1, Lina Pantazi5, Kyriaki A. Boki5, Eleftheria P. Grika1, Panagiotis G. Vlachoyiannopoulos1, Konstantina Karagianni6, Lazaros I. Sakkas6, Theodoros Dimitroulas7, Alexandros Garyfallos7, Dimitrios Kassimos8, Gerasimos Evangelatos9, Alexios Iliopoulos9, Maria Areti10, Constantinos Georganas10, Konstantinos Melissaropoulos11, Panagiotis Georgiou11, Periklis Vounotrypidis10, Konstantinos Ntelis10, Clio P. Mavragani1, Ilias Bournazos10, Gikas Katsifis12, Christos Mavrommatis10, George D. Kitas1,13, Dimitrios Vassilopoulos1
Authors Information

1: Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

2: Rheumatology Clinic, University of Ioannina, Ioannina, Greece

3: Clinical Immunology and Allergy Department, University of Crete, Heraklion, Greece

4: Rheumatology Unit, KAT Hospital, Athens, Greece

5: Rheumatology Unit, Sismanoglio Hospital, Athens, Greece

6: Department of Rheumatology, University of Thessaly, Larissa, Greece

7: 4th Department of Medicine, Aristotle University, Thessaloniki, Greece

8: 401 General Military Hospital, Athens, Greece

9: Rheumatology Unit, NIMTS Hospital, Athens, Greece

10: Private Practice, Greece

11: Rheumatology Unit, Agios Andreas Hospital, Patras, Greece

12: Rheumatology Unit, Navy Hospital, Athens, Greece

13: Hygeia Hospital, Athens, Greece
Keywords: rheumatoid arthritis, comorbidities, biologics, methotrexate, vaccination, infections, tuberculosis, hepatitis, cardiovascular diseases
References
  1. Smolen J S, Aletaha D, McInnes I B. Rheumatoid arthritis. Lancet 2016;388:2023-38.
  2. Alamanos Y, Voulgari P V, Drosos A A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36:182-8.
  3. Andrianakos A, Trontzas P, Christoyannis F, Kaskani E, Nikolia Z, Tavaniotou E, et al. Prevalence and management of rheumatoid arthritis in the general population of Greece--the ESORDIG study. Rheumatology (Oxford) 2006;45:1549-54.
  4. Drosos A A, Alamanos I, Voulgari P V, Psychos D N, Katsaraki A, Papadopoulos I, et al. Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J Rheumatol 1997;24:2129-33.
  5. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou A A, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord 2010;11:98.
  6. Guillemin F, Saraux A, Guggenbuhl P, Roux C H, Fardellone P, Le B E, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005;64:1427-30.
  7. Flouri I, Markatseli T E, Voulgari P V, Boki K A, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014;43:447-57.
  8. Lampropoulos C E, Orfanos P, Bournia V K, Karatsourakis T, Mavragani C, Pikazis D, et al. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clin Exp Rheumatol 2015;33:216-24.
  9. Vassilopoulos D, Delicha E M, Settas L, Andrianakos A, Aslanidis S, Boura P, et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clin Exp Rheumatol 2016;34:893-900.
  10. Thomas K, Flouri I, Repa A, Fragiadaki K, Sfikakis P P, Koutsianas C, et al. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clin Exp Rheumatol 2017.
  11. Souto A, Maneiro J R, Gomez-Reino J J. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 2016;55:523-34.
  12. Hudson M, Tascilar K, Suissa S. Comparative effectiveness research with administrative health data in rheumatoid arthritis. Nat Rev Rheumatol 2016;12:358-66.
  13. Michaud K, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg J D, et al. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis 2016;75:1797-805.
  14. Solomon D H, Reed G W, Kremer J M, Curtis J R, Farkouh M E, Harrold L R, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67:1449-55.
  15. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch M H, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
  16. Singh J A, Saag K G, Bridges S L Jr., Akl E A, Bannuru R R, Sullivan M C, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1-26.
  17. Smolen J S, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
  18. Smolen J S, Breedveld F C, Burmester G R, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
  19. Sfikakis P P, Bournia V K, Sidiropoulos P, Boumpas D T, Drosos A A, Kitas G D, et al. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017;35:579-85.
  20. Pappas D A, Reed G W, Saunders K, John A, Shewade A, Greenberg J D, et al. Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population. Rheumatol Ther 2015;2:85-96.
  21. Gabay C, Riek M, Scherer A, Finckh A. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 2015;54:1664-72.
  22. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007;46:350-7.
  23. Pinheiro F A, Souza D C, Sato E I. A Study of Multiple Causes of Death in Rheumatoid Arthritis. J Rheumatol 2015;42:2221-8.
  24. Karvounaris S A, Sidiropoulos P I, Papadakis J A, Spanakis E K, Bertsias G K, Kritikos H D, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007;66:28-33.
  25. Protogerou A D, Panagiotakos D B, Zampeli E, Argyris A A, Arida K, Konstantonis G D, et al. Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther 2013;15:R142.
  26. Gogos C A, Fouka K P, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H, et al. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003;18:551-7.
  27. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2017. Accessed at: ecdc.europa.eu/sites/portal/files/documents/ecdc-tuberculosis-surveillance-monitoring-Europe-2017-WEB.pdf on January 5, 2018.
  28. Lytras T, Spala G, Bonovas S, Panagiotopoulos T. Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption. PLoS One 2012;7:e50033.
  29. Houben R M, Dodd P J. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 2016;13:e1002152.
  30. Carmona L, Gomez-Reino J J, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola E M, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
  31. Thomas K, Vassilopoulos D. Immunization in patients with inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2016;30:946-63.